Evidence map›Paper›PMID 38667286›Full record

ArticleCells2024

Human-Induced Pluripotent Stem Cell-Derived Neural Progenitor Cells Showed Neuronal Differentiation, Neurite Extension, and Formation of Synaptic Structures in Rodent Ischemic Stroke Brains.

Yonehiro Kanemura, Atsuyo Yamamoto, Asako Katsuma, Hayato Fukusumi, Tomoko Shofuda, Daisuke Kanematsu, Yukako Handa, Miho Sumida, Ema Yoshioka, Yutaka Mine and 7 more

Abstract read
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Molecular imaging of stem cell therapies in ischemic stroke.European journal of nuclear medicine and molecular imaging · 2025
    Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yonehiro KanemuraDepartment of Biomedical Research and Innovation, Institute for Clinical Research, NHO Osaka National Hospital, Osaka 540-0006, Japan.ORCID 0000-0002-1894-1824
Atsuyo YamamotoDepartment of Biomedical Research and Innovation, Institute for Clinical Research, NHO Osaka National Hospital, Osaka 540-0006, Japan.
Asako KatsumaDepartment of Biomedical Research and Innovation, Institute for Clinical Research, NHO Osaka National Hospital, Osaka 540-0006, Japan.
Hayato FukusumiDepartment of Biomedical Research and Innovation, Institute for Clinical Research, NHO Osaka National Hospital, Osaka 540-0006, Japan.
Tomoko ShofudaDepartment of Biomedical Research and Innovation, Institute for Clinical Research, NHO Osaka National Hospital, Osaka 540-0006, Japan.
Daisuke KanematsuDepartment of Biomedical Research and Innovation, Institute for Clinical Research, NHO Osaka National Hospital, Osaka 540-0006, Japan.
Yukako HandaDepartment of Biomedical Research and Innovation, Institute for Clinical Research, NHO Osaka National Hospital, Osaka 540-0006, Japan.
Miho SumidaDepartment of Biomedical Research and Innovation, Institute for Clinical Research, NHO Osaka National Hospital, Osaka 540-0006, Japan.
Ema YoshiokaDepartment of Biomedical Research and Innovation, Institute for Clinical Research, NHO Osaka National Hospital, Osaka 540-0006, Japan.
Yutaka MineDepartment of Neurosurgery, NHO Tokyo Medical Center, Tokyo 152-8902, Japan.ORCID 0000-0003-4665-132X
Ryo YamaguchiDepartment of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan.
Masayasu OkadaDepartment of Brain Tumor Biology, Brain Research Institute, Niigata University, Niigata 951-8585, Japan.ORCID 0000-0002-9151-8184
Michihiro IgarashiDepartment of Neurochemistry and Molecular Cell Biology, School of Medicine, Graduate School of Medical, Dental Sciences Niigata University, Niigata 951-8510, Japan.
Yuko SekinoDepartment of Veterinary Pathophysiology and Animal Health, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo 113-8657, Japan.
Tomoaki ShiraoAlzMed, Inc., Tokyo 113-8485, Japan.
Masaya NakamuraDepartment of Orthopaedic Surgery, Keio University School of Medicine, Tokyo 160-8582, Japan.
Hideyuki OkanoDepartment of Physiology, Keio University School of Medicine, Tokyo 160-8582, Japan.ORCID 0000-0001-7482-5935

Funding

Japan Agency for Medical Research and Development JP15bm0204001Japan Agency for Medical Research and Development JP23bk0104161
6 · The paper itself

Abstract

Ischemic stroke is a major cerebrovascular disease with high morbidity and mortality rates; however, effective treatments for ischemic stroke-related neurological dysfunction have yet to be developed. In this study, we generated neural progenitor cells from human leukocyte antigen major loci gene-homozygous-induced pluripotent stem cells (hiPSC-NPCs) and evaluated their therapeutic effects against ischemic stroke. hiPSC-NPCs were intracerebrally transplanted into rat ischemic brains produced by transient middle cerebral artery occlusion at either the subacute or acute stage, and their in vivo survival, differentiation, and efficacy for functional improvement in neurological dysfunction were evaluated. hiPSC-NPCs were histologically identified in host brain tissues and showed neuronal differentiation into vGLUT-positive glutamatergic neurons, extended neurites into both the ipsilateral infarct and contralateral healthy hemispheres, and synaptic structures formed 12 weeks after both acute and subacute stage transplantation. They also improved neurological function when transplanted at the subacute stage with γ-secretase inhibitor pretreatment. However, their effects were modest and not significant and showed a possible risk of cells remaining in their undifferentiated and immature status in acute-stage transplantation. These results suggest that hiPSC-NPCs show cell replacement effects in ischemic stroke-damaged neural tissues, but their efficacy is insufficient for neurological functional improvement after acute or subacute transplantation. Further optimization of cell preparation methods and the timing of transplantation is required to balance the efficacy and safety of hiPSC-NPC transplantation.

Indexed as

Cell DifferentiationInduced Pluripotent Stem CellsIschemic StrokeNeural Stem CellsSynapsesAnimalsBrainBrain IschemiaHumansMaleNeuritesNeuronsRatsRats, Sprague-DawleyStrokecell replacement effectinduced pluripotent stem cellsintracerebral transplantationischemic strokeneural progenitor cellsneurite extensionneuronal differentiationsynaptic structure formation

Identifiers

PMID38667286
PMCPMC11048851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.